Compounds > methamphetamine

methamphetamine and Basal Ganglia Diseases

methamphetamine has been researched along with Basal Ganglia Diseases in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kaneko, T; Kobayashi, K; Kohno, K; Matsushita, N; Pastan, I; Sano, H; Yasoshima, Y1
Glickstein, SB; Schmauss, C1
Matsuoka, N; Mutoh, S; Shirakawa, K; Tada, M1
Endo, S; Ishibashi, S; Katsumata, N; Kuroiwa, T; Mizusawa, H; Yuan, SL1
Harvey, DC; Laćan, G; Melega, WP; Way, BM1

Other Studies

5 other study(ies) available for methamphetamine and Basal Ganglia Diseases

ArticleYear
Conditional ablation of striatal neuronal types containing dopamine D2 receptor disturbs coordination of basal ganglia function.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2003, Oct-08, Volume: 23, Issue:27

    Topics: Animals; Basal Ganglia; Basal Ganglia Diseases; Binding, Competitive; Corpus Striatum; Dopamine Agents; Drug Administration Routes; Gene Expression; Gene Targeting; Humans; Immunotoxins; Interleukin-2 Receptor alpha Subunit; Ligands; Methamphetamine; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Mice, Transgenic; Motor Activity; Neurons; Promoter Regions, Genetic; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Interleukin

2003
Focused motor stereotypies do not require enhanced activation of neurons in striosomes.
    The Journal of comparative neurology, 2004, Feb-02, Volume: 469, Issue:2

    Topics: Animals; Basal Ganglia Diseases; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Immunohistochemistry; Male; Methamphetamine; Mice; Mice, Inbred C57BL; Mice, Knockout; Neostriatum; Neural Pathways; Neurons; Neuropil; Predictive Value of Tests; Proto-Oncogene Proteins c-fos; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; Stereotypic Movement Disorder; Synaptic Transmission

2004
Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
    Psychopharmacology, 2004, Volume: 176, Issue:1

    Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Administration, Oral; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Catalepsy; Chlorpromazine; Dibenzothiazepines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Haloperidol; Hyperkinesis; Injections, Intraperitoneal; Male; Methamphetamine; Mice; Piperazines; Pyridines; Quetiapine Fumarate; Receptor, Serotonin, 5-HT1A; Risperidone; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists

2004
Extrapyramidal motor symptoms versus striatal infarction volume after focal ischemia in mongolian gerbils.
    Neuroscience, 2004, Volume: 127, Issue:2

    Topics: Animals; Basal Ganglia Diseases; Brain Infarction; Brain Ischemia; Corpus Striatum; Disease Models, Animal; Dopamine; Female; Functional Laterality; Gerbillinae; Hippocampus; Infarction, Middle Cerebral Artery; Male; Methamphetamine; Movement Disorders; Neurons; Rotation; Substantia Nigra

2004
Methamphetamine increases basal ganglia iron to levels observed in aging.
    Neuroreport, 2007, Oct-29, Volume: 18, Issue:16

    Topics: Aging; Animals; Basal Ganglia; Basal Ganglia Diseases; Central Nervous System Stimulants; Chlorocebus aethiops; Disease Models, Animal; Dopamine; Ferritins; Globus Pallidus; Iron; Iron Metabolism Disorders; Male; Methamphetamine; Oxidative Stress; Species Specificity; Substantia Nigra; Tyrosine 3-Monooxygenase

2007